We are committed to the development of novel treatments for people affected by CNS disorders

Autobahn Therapeutics is conducting clinical research on innovative treatments for major depressive disorder (MDD) and bipolar disorder depression. Through collaboration with clinical experts, patient advocacy organizations, and disease communities, we are taking a patient- and caregiver-centric approach to the development of our product candidates. Our current trials evaluate ABX-002, our novel thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment for MDD and bipolar depression. ABX-002 has been designed to enhance brain function through validated mechanisms of action, such as improving brain bioenergetics and cellular energy metabolism. Explore our active trials below and learn about our next-generation treatments for central nervous system (CNS) disorders.